GI Bleeding Risk of DOACs Versus Warfarin: Is Newer Better?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Construction of a risk scoring system using clinical factors andFrontiers in pharmacology · 2023
   Article
2. Gastrointestinal bleeding risk of non-vitamin K antagonist oral anticoagulants versus warfarin in general and after polypectomy: a population-based study with propensity score matching analysis.Intestinal research · 2022
   Article
3. Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease.Frontiers in cardiovascular medicine · 2021
   Article
4. Major gastrointestinal bleeding and antithrombotics: Characteristics and management.World journal of gastroenterology · 2020
   Article
5. Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System.Frontiers in pharmacology · 2019
   Article

Corrections and comments

• Comment on
  Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as